Search results for "VLPs" in Articles / App Notes
Article
Accelerating VLP purification process development
Indeed, a method for the large-scale production of VLPs is production in suspension cell culture, and extracting the VLPs from the cell culture supernatant is a time and labor-intensive process.
…
Article
Virus-like Particles as Therapeutic Moieties of the Future
Rathore
Virus-like particles (VLPs) are viral capsid shells assembled without encapsulated nucleic acid. These particles resemble native virions, are highly ordered and repetitive, and are approxi…
Article
Genetic Vaccine Platforms Demonstrate Their Potential
In a pandemic, genetic vaccines offer several advantages over traditional approaches.
By Cynthia A. Challener
For a vaccine to be effective, the components of the disease o…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Similar to viral vectors, VLPs present unique challenges because of their large size (2.5 x106 kDa). Q (14 kDa) is the most commonly used VLP. It is derived from the structural coat protein of this vi…
Article
Ensuring Viral Safety of Viral Vaccines and Vectors
Sf9 cells are a common substrate for biological products such as VLPs.
These contamination events highlight the limitations of current technologies; more vigilance is needed. Consequences of va…
Article
Generating a Fully Processed Antibody
Many VLPs, for example, require two or more proteins to be produced in the right proportion to get the correct viral structure to mimic the virus itself.
In the case of a protein needing cleavage …
Article
Novel Vaccine Technologies Meet the Need for Pandemic and Therapeutic Solutions
Two different types of immunogenic particles are used: virus-like particles (VLPs) and recombinant protein micelles. Novavax’ seasonal and pandemic influenza vaccines consist of VLPs or recombinant pa…